TELA Bio, Inc. (TELA)

NASDAQ: TELA · IEX Real-Time Price · USD
7.08
+0.32 (4.73%)
Mar 1, 2024, 4:00 PM EST - Market closed
4.73%
Market Cap 173.38M
Revenue (ttm) 53.08M
Net Income (ttm) -43.75M
Shares Out 24.49M
EPS (ttm) -2.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,062
Open 6.82
Previous Close 6.76
Day's Range 6.62 - 7.17
52-Week Range 4.24 - 11.65
Beta 0.99
Analysts Strong Buy
Price Target 14.67 (+107.2%)
Earnings Date Mar 21, 2024

About TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Nov 8, 2019
Employees 173
Stock Exchange NASDAQ
Ticker Symbol TELA
Full Company Profile

Financial Performance

In 2022, TELA Bio's revenue was $41.42 million, an increase of 40.58% compared to the previous year's $29.46 million. Losses were -$44.30 million, 33.1% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for TELA stock is "Strong Buy." The 12-month stock price forecast is $14.67, which is an increase of 107.20% from the latest price.

Price Target
$14.67
(107.20% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results

MALVERN, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...

3 days ago - GlobeNewsWire

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Feb. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...

9 days ago - GlobeNewsWire

TELA Bio to Take Part in Connecting the Dots

MALVERN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that ...

3 months ago - GlobeNewsWire

TELA Bio to Participate in Piper Sandler's 35th Annual Healthcare Conference

MALVERN, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that ...

3 months ago - GlobeNewsWire

TELA Bio Reports Third Quarter 2023 Financial Results

MALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that opt...

4 months ago - GlobeNewsWire

TELA Bio to Announce Third Quarter 2023 Financial Results

MALVERN, Pa., Oct. 26, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...

4 months ago - GlobeNewsWire

TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase

MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...

5 months ago - GlobeNewsWire

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

New addition expands reconstruction options for surgeons and patients New addition expands reconstruction options for surgeons and patients

7 months ago - GlobeNewsWire

TELA Bio Reports Second Quarter 2023 Financial Results

MALVERN, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that opt...

7 months ago - GlobeNewsWire

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

MALVERN, Pa., July 26, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...

7 months ago - GlobeNewsWire

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

Survey of more than 1,000 consumers demonstrates concerns over permanent synthetic mesh and highlights a strong desire for shared decision-making and surgeon expertise in innovative, more natural opti...

9 months ago - GlobeNewsWire

TELA Bio to Participate in the Jefferies Global Healthcare Conference

MALVERN, Pa., May 25, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize...

10 months ago - GlobeNewsWire

TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab

Company prioritizes education with a variety of in-person and virtual training programs Company prioritizes education with a variety of in-person and virtual training programs

10 months ago - GlobeNewsWire

TELA Bio Reports First Quarter 2023 Financial Results

MALVERN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that opti...

10 months ago - GlobeNewsWire

TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference

Leader in innovative soft-tissue tissue reconstruction solutions sponsors event advocating for and mentoring women in surgery Leader in innovative soft-tissue tissue reconstruction solutions sponsors ...

10 months ago - GlobeNewsWire

TELA Bio to Participate in the JMP Securities Life Sciences Conference

MALVERN, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize...

10 months ago - GlobeNewsWire

TELA Bio to Announce First Quarter 2023 Financial Results

MALVERN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction so...

11 months ago - GlobeNewsWire

Why TELA Bio Stock Is Dropping Today - TELA Bio (NASDAQ:TELA)

TELA Bio TELA shares are trading lower after the company priced a 4.75 million share offering at $9.50 per share.

11 months ago - Benzinga

TELA Bio Announces Pricing of Public Offering of Common Stock

MALVERN, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimi...

11 months ago - GlobeNewsWire

TELA Bio Announces Proposed Public Offering of Common Stock

MALVERN, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimi...

11 months ago - GlobeNewsWire

TELA Bio's OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

Presentations highlight utility of this advanced hernia reinforcement material for robotic procedures Presentations highlight utility of this advanced hernia reinforcement material for robotic procedu...

1 year ago - GlobeNewsWire

TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Company continues design advancements of biologic-based materials for soft tissue repair and reinforcement Company continues design advancements of biologic-based materials for soft tissue repair and ...

1 year ago - GlobeNewsWire

TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results

MALVERN, Pa., March 21, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that op...

1 year ago - GlobeNewsWire

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

Recent research of OviTex® Reinforced Tissue Matrix demonstrated favorable results in various hernia and abdominal wall reconstruction applications Recent research of OviTex® Reinforced Tissue Matrix ...

1 year ago - GlobeNewsWire

TELA Bio to Announce Fourth Quarter and Full Year 2022 Financial Results

MALVERN, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...

1 year ago - GlobeNewsWire